EconPapers    
Economics at your fingertips  
 

A melanocyte lineage program confers resistance to MAP kinase pathway inhibition

Cory M. Johannessen, Laura A. Johnson, Federica Piccioni, Aisha Townes, Dennie T. Frederick, Melanie K. Donahue, Rajiv Narayan, Keith T. Flaherty, Jennifer A. Wargo, David E. Root and Levi A. Garraway ()
Additional contact information
Cory M. Johannessen: The Broad Institute of Harvard University and Massachusetts Institute of Technology, 7 Cambridge Center
Laura A. Johnson: The Broad Institute of Harvard University and Massachusetts Institute of Technology, 7 Cambridge Center
Federica Piccioni: The Broad Institute of Harvard University and Massachusetts Institute of Technology, 7 Cambridge Center
Aisha Townes: The Broad Institute of Harvard University and Massachusetts Institute of Technology, 7 Cambridge Center
Dennie T. Frederick: Medical Oncology and Dermatology, Massachusetts General Hospital, 55 Fruit Street, Boston, Massachusetts 02114, USA
Melanie K. Donahue: The Broad Institute of Harvard University and Massachusetts Institute of Technology, 7 Cambridge Center
Rajiv Narayan: The Broad Institute of Harvard University and Massachusetts Institute of Technology, 7 Cambridge Center
Keith T. Flaherty: Medical Oncology and Dermatology, Massachusetts General Hospital, 55 Fruit Street, Boston, Massachusetts 02114, USA
Jennifer A. Wargo: Medical Oncology and Dermatology, Massachusetts General Hospital, 55 Fruit Street, Boston, Massachusetts 02114, USA
David E. Root: The Broad Institute of Harvard University and Massachusetts Institute of Technology, 7 Cambridge Center
Levi A. Garraway: The Broad Institute of Harvard University and Massachusetts Institute of Technology, 7 Cambridge Center

Nature, 2013, vol. 504, issue 7478, 138-142

Abstract: Expression of more than 15,500 genes individually in a melanoma cell line treated with RAF, MEK, ERK or combined RAF–MEK inhibitors reveals a cyclic-AMP-dependent melanocytic signalling network associated with drug resistance; this may represent a novel therapeutic target for melanoma treatment.

Date: 2013
References: Add references at CitEc
Citations: View citations in EconPapers (3)

Downloads: (external link)
https://www.nature.com/articles/nature12688 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:504:y:2013:i:7478:d:10.1038_nature12688

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature12688

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

 
Page updated 2025-03-19
Handle: RePEc:nat:nature:v:504:y:2013:i:7478:d:10.1038_nature12688